Ge Long Hui·2025-12-09 11:20Core Viewpoint - Fosun Pharma has signed a licensing agreement with Pfizer for the exclusive development, use, production, and commercialization rights of the oral small molecule GLP-1 receptor agonist YP05002, which is aimed at treating type 2 diabetes and obesity-related diseases [1] Group 1: Licensing Agreement Details - The agreement was signed on December 9, 2025, between Fosun Pharma's subsidiary, YaoYao Pharmaceutical, and Pfizer [1] - YaoYao Pharmaceutical will receive an upfront payment of $15 million and potential milestone payments up to $35 million based on clinical and commercialization progress of the licensed product [1] Group 2: Product Information - YP05002 is an independently developed oral small molecule GLP-1 receptor agonist with proprietary intellectual property [1] - The mechanism of YP05002 includes promoting insulin secretion from the pancreas, reducing glucagon secretion, inhibiting gastric emptying, and suppressing appetite to reduce energy intake [1] - Potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related non-alcoholic steatohepatitis [1]